BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects
- Mutations in the BRCA1 and BRCA2 genes predispose to breast and ovarian cancer, and are
increasingly recognized in prostate and pancreatic cancers.
- Basal/ Triple negative breast cancer is associated with BRCA mutations in some
ethnicities.However the link between BRCA gene mutations and Basil/ triple negative
disease in Hispanic/ Latino women is not known.
- Common recurrent mutations in BRCA1 and BRCA2 exist in Hispanic/ Latino communities.
- New therapies such as PARP inhibitors may be particularly effective in BRCA mutation
- Therefore a unique opportunity exists to identify women in this underserved minority
that may be eligible for and benefit from new targeted therapies.
- The primary objective is to collect saliva samples and histology data from up to 2000
Hispanic/ Latino subjects with breast cancer as a source of DNA, and to analyze the BRCA1
and BRCA2 genes..
- All Hispanics females, over the age of 18, with breast cancer will be eligible.
- Natural history study of 2000 Hispanic/Latino women with breast cancer, 1000 with triple
negative disease, 1000 without.
- Obtain clinical pathology reports and relevant history data on all subjects.
- Analyze recurrent BRCA1 and BRCA2 mutations
Michael Dean, Ph.D.
National Cancer Institute (NCI)
United States: Federal Government
|Texas Tech University Health Sciences Center University Health Sciences Center||El Paso, Texas|
|Southwest Cancer Treatment and Research Center, Lubbock; Texas Tech University||Lubbock, Texas 79415|